Paul Tudor Jones C4 Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.05 - $8.1 $41,156 - $82,312	10,162 New	10,162 $46,000
Q3 2023 Nov 15, 2023	BUY	$1.81 - $3.89 $27,553 - $59,217	15,223 New	15,223 $28,000
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $74,294 - $216,173	23,966 New	23,966 $75,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $112 - $178	14 Added 0.06%	24,134 $212,000
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $122,047 - $638,215	24,120 New	24,120 $182,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $425,447 - $707,234	-21,283 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $625,507 - $997,321	21,283 New	21,283 $685,000

129

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $164M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.